The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020
Open accessPublished version of a preprint
Abstract
Abstract Background The extent of infection by coronavirus disease 2019 has not been well known. In this study we aimed to determine seropositivity of COVID-19 virus infection in population of a highly affected area in north of Iran. Methods In a population-based cluster random sampling design through phone call invitation, a total of 196 household including 551 subjects agreed to participate in this study. Each participant were taken 50ml blood sample at health care center. Rapid test kits were used to detect antibody against COVID-19. Crude, population-weight adjusted and test performance adjusted prevalence of antibody seropositivity to SARS-CoV-2 were reported. Results The prevalence of antibody seropositivity was 22% (95%CI: 19-26%). The population weight adjusted estimate was 21% (95%CI: 14-29%) and test performance adjusted prevalence was 33% (95%CI: 28-39%). Based on these estimates the range of infected people in this province would be between 518000 and 777000. Conclusion The population seropositivity prevalence of COVID-19 virus infection indicated that the asymptomatic infection is much higher than the number of confirmed cases of COVID-19. This estimate can be used to better detect infection fatality rate and decide for public policy guidelines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy
Onder, G., Rezza, G., & Brusaferro, S. (2020) · JAMA · doi:10.1001/jama.2020.4683 · Cited by 4,171
Pollán, M., Pérez-Gómez, B., Pastor-Barriuso, R., Oteo, J., Hernán, M. A., Pérez-Olmeda, M., Sanmartín, J. L., Fernández-García, A., Cruz, I., Fernández de Larrea, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31483-5 · Cited by 1,639
Research works printed but not linked: 8
- Russell, 2020, Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020., Euro Surveill, 25, 2000256, 10.2807/1560-7917.ES.2020.25.12.2000256 · DOI · Paper page
- Clapham, 2020, Seroepidemiologic study designs for determining SARS-COV-2 transmission and immunity., Emerg Infect Dis, 26, 1978, 10.3201/eid2609.201840 · DOI
- Mansournia, 2016, Inverse probability weighting., BMJ, 352, i189, 10.1136/bmj.i189 · DOI · Paper page
- Cassaniti, 2020, Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department., J Med Virol, 92, 1724, 10.1002/jmv.25800 · DOI · Paper page
- Van Elslande, 2020, Diagnostic performance of seven rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients., Clin Microbiol Infect, 26, 1082, 10.1016/j.cmi.2020.05.023 · DOI · Paper page
- Sood, 2020, Seroprevalence of SARS-CoV-2-specific antibodies among adults in Los Angeles County, California, on April 10–11, 2020., JAMA, 323, 2425, 10.1001/jama.2020.8279 · DOI · Paper page
- Stringhini, 2020, Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study., Lancet, 396, 313, 10.1016/S0140-6736(20)31304-0 · DOI · Paper page
- Bhatraju, 2020, Covid-19 in critically ill patients in the Seattle region—case series., N Engl J Med, 382, 2012, 10.1056/NEJMoa2004500 · DOI · Paper page
Cited by
Pollán, M., Pérez-Gómez, B., Pastor-Barriuso, R., Oteo, J., Hernán, M. A., Pérez-Olmeda, M., Sanmartín, J. L., Fernández-García, A., Cruz, I., Fernández de Larrea, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31483-5 · Cited by 1,639
Viner, R. M., Mytton, O. T., Bonell, C., Melendez-Torres, G. J., Ward, J., Hudson, L., Waddington, C., Thomas, J., Russell, S., van der Klis, F., et al. (2021) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2020.4573 · Cited by 835
Infection fatality rate of COVID-19 inferred from seroprevalence data
Ioannidis, J. P. A. (2021) · Bulletin of the World Health Organization · doi:10.2471/blt.20.265892 · Cited by 684
Meyerowitz-Katz, G., & Merone, L. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.09.1464 · Cited by 566
La Marca, A., Capuzzo, M., Paglia, T., Roli, L., Trenti, T., & Nelson, S. M. (2020) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2020.06.001 · Cited by 389
SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis
Rostami, A., Sepidarkish, M., Leeflang, M. M. G., Riahi, S. M., Nourollahpour Shiadeh, M., Esfandyari, S., Mokdad, A. H., Hotez, P. J., & Gasser, R. B. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.10.020 · Cited by 369
Ioannidis, J. P. A., Axfors, C., & Contopoulos-Ioannidis, D. G. (2020) · Environmental Research · doi:10.1016/j.envres.2020.109890 · Cited by 331
Nkuba, A. N., Makiala, S. M., Guichet, E., Tshiminyi, P. M., Bazitama, Y. M., Yambayamba, M. K., Kazenza, B. M., Kabeya, T. M., Matungulu, E. B., Baketana, L. K., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab515 · Cited by 51
Metadata
- Authors
- Shakiba, M., Nazemipour, M., Salari, A., Mehrabian, F., Nazari, S. S. H., Rezvani, S. M., Ghasempour, Z., Heidarzadeh, A., & Mansournia, M. A.
- Venue
- Emerging Infectious Diseases
- Published
- 2021-02
- Volume
- 27
- Issue
- 2
- Pages
- 636-638
- ISSN
- 1080-6040 (ISSN-L)
- 1080-6059
- OpenAlex
- W3115246226
- Cited by
- 164
- References
- 2
- FWCI
- 4.59
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.